Watson Full Year 2011 Net Revenue Increases 29% to $4.5... (808.0Long-term debt 848.51016.1Deferr...)

Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion;

Date:2/14/2012

808.0Long-term debt

848.51,016.1Deferred income taxes and other liabilities

447.8579.9Total equity

3,562.53,282.6Total liabilities and equity

$
,698.3$
5,686.6The following table presents Watson's Condensed Consolidated Statements of Cash Flows for the twelve months ended December 31, 2011 and 2010.Table 3Watson Pharmaceuticals, Inc.Condensed Consolidated Statements of Cash Flows(Unaudited; in millions)Twelve Months EndedDecember 31,20112010CASH FLOWS FROM OPERATING ACTIVITIES:Net income$
259.1$
83.3Reconciliation to net cash provided by operating activities:Depreciation93.6101.9Amortization354.3180.0Provision for inventory reserve44.450.0Share based compensation39.823.5Deferred income tax benefit(123.3)(118.3)Losses on equity method investments4.5-Gain on sale of securities(0.8)(27.3)Loss on asset sales and impairments, net76.329.8Increase in allowance for doubtful accounts2.39.5Accretion of discount on preferred stock and contingent consideration obligation14.638.4Excess tax benefit from stock-based compensation(14.6)-Other, net(0.2)11.3Changes in assets and liabilities:Accounts receivable, net(590.9)(57.1)Inventories(282.2)10.5Prepaid expenses and other current assets43.555.4Accounts payable and accrued expenses671.896.5Deferred revenue(8.7)(10.6)Income and other taxes payable81.9(20.8)Other assets and liabilities(33.4)15.0 Total adjustments372.9387.7Net cash provided by operating activities632.0571.0CASH FLOWS FROM INVESTING ACTIVITIES:Additions to property and equipment(126.7)(56.6)Acquisition of product rights and other intangibles(18.7)(10.9)Additions to marketable securities(10.0)(5.5)Additions to long-term investments(3.6)(43.7)Proceeds from sale of property and equipment6.72.7Proceeds from sales of marketable securities5.39.5Proceeds from sale of investments0.895.4Acquisition of business, net of cash acquired(575.1)(67.5)Other investing activities, net2.32.5Net cash used in investing activities(719.0)(74.1)CASH
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)

Post Your Comments:

(Date:5/22/2013)... , May 22, 2013 PRNewswire – ... production of a vaccine candidate for the newly ... party laboratory using the iBioLaunch™ platform. This validation ... from initial antigen sequence information to purification of ... ) The iBioLaunch platform eliminates ...

(Date:5/22/2013)... WomanCare Global recently launched Simplant in ... training initiative attended by 90 health care providers. ... http://photos.prnewswire.com/prnh/20101018/DC83896LOGO ) Simplant, a long-acting ... subdermal implant composed of two thin, flexible, silicone ... form of the hormone progestin). These are inserted ...

(Date:5/21/2013)... BEIJING, May 21, 2013 Concord Medical Services ... CCM ), a leading specialty hospital management solution ... and diagnostic imaging centers in China and the parent ... results for the first quarter ended March 31, 2013 ... , Total net revenue, which consists of net revenues ...

[0] iBio Technology Produces Vaccine Candidate for Recently Emerged H7N9 Influenza [0] WomanCare Global launches Simplant, Long-acting Reversible Contraception, in Chile [0] Concord Medical Reports First Quarter 2013 Financial Results

... (Nasdaq: IDEV ) today announced that it ... and Drug Administration (FDA) for,VALSTAR(R). VALSTAR, a sterile ... product approved by the FDA for therapy of,bacillus ... bladder. VALSTAR was removed from the market ...

... 17 Dendreon Corporation,(Nasdaq: DNDN ) today ... study,of NEUVENGE, an investigational active cellular immunotherapy, in ... Oncology. The article highlights,the safety profile, immune response ... breast cancer who have failed standard,therapy. "In ...

Cached Medicine Technology:Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 2 Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 3 Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 4 Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 2 Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 3 Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 4

Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients

(Date:5/22/2013)... from a large observational study reported at ... superior to heparin in the absence of ... patients with non-ST segment elevation acute coronary ... European and US NSTE-ACS guidelines currently recommend ... heparin plus GP IIb/IIIa receptor inhibitors in ...

(Date:5/22/2013)... MA (PRWEB) May 22, 2013 In ... hit the country’s fields and courts with donated ... Sports, a Massachusetts-based nonprofit dedicated to partnering with manufacturers ... is celebrating the donation of $8.8 million in sports ... more than a half-million kids outfitted for physical activity. ...

(Date:5/22/2013)... Following the success of last year’s ... Fit Body Boot Camp Kincardine has announced it will ... starting on June 3rd at its Kincardine fitness ... Kincardine, Ontario. , Fit Body Boot Camp’s 1,000 lb. ... community residents to lose a total of 1,000 pounds ...

(Date:5/22/2013)... Jersey City, NJ (PRWEB) May 22, 2013 ... governance, compliance, and management solutions for social enterprise ... Partners, LLC, a consulting firm based in Chicago, ... to integrate their products and provide best-in-class solutions ... productivity and improve collaboration. , AvePoint’s DocAve ...

(Date:5/22/2013)... adherence to appropriate medication therapy has been shown to ... 125,000 deaths in the U.S. every year are attributed ... estimated that between 33% and 69% of all medication-related ... a reality that costs the American health-care system approximately ... degree of medication non-adherence — and the consequences therefrom ...

Breaking Medicine News(10 mins):Health News:Registry questions superiority of bivalirudin over heparin 2 Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 2 Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 3 Health News:Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 2 Health News:Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 3 Health News:AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration 2 Health News:AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration 3 Health News:Patient Prompt® Announces New Drug Adherence Program to Assist in Prescribed Medication Compliance 2

[0] Registry questions superiority of bivalirudin over heparin [0] Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity [0] Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity [0] AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration [0] Patient Prompt® Announces New Drug Adherence Program to Assist in Prescribed Medication Compliance

... 25 Former NFL player and Dallas Cowboy,Jason Kaiser ... graduation ceremony. Kaiser earned the title of,valedictorian with a ... people in,this school and in my class especially," he ... Before enrolling in Parker College, Kaiser played professional football,for ...

... protein levels could key future treatments for Alzheimer,s , , ... finds that where protein-destroying machines reside in the brain,s ... a finding that may play a role in future ... Wake Forest University School of Medicine researchers studying mice ...

... his left eyebrow was possibly skin cancer , , FRIDAY, ... during his lifetime, historians have gone to great lengths ... of Franklin Delano Roosevelt, the 32nd president of the ... and heart disease is now well-documented. But a new ...

... QLT Inc. (NASDAQ: QLTI;,TSX: QLT) today reported financial results ... otherwise, all amounts are in U.S. dollars,and in accordance ... 2008, we were pleased to report the U.S. Food,and ... blood,monitoring from the Aczone(TM) label," said Bob Butchofsky, President ...

... Inc., (a wholly owned,subsidiary of Mentice AB), a ... the field of medicine, has recently appointed,Jeff Sirek ... Clinical,Applications Manager for the Americas., Jeff Sirek ... years with GE Healthcare in its Cardiovascular Ultrasound,Division ...

... Solutions, Inc. announced,today the addition of Dr. Marc ... serve as Vice President of Research and Development ... of spine,system/orthopedic development experience, most recently having directed,development ... Marc to Facet Solutions bolsters an already great,team, ...

Former Dallas Cowboy Honored as Parker College of Chiropractic Top 2008 Graduate When It Comes to Memory, It's All About Location FDR Might Have Had Melanoma QLT announces first quarter results for 2008 Mentice, Inc. Expands Its North American Sales and Clinical Presence With the Hiring of Jeff Sirek as Director of Educational Sales-East and Sue Landsman as Clinical Applications Manager for the Americas.Facet Solutions, Inc. Expands Executive Management Team

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

Medicine Products:

Netromycin, Random Level Netilmicin, Random Level Neopterin Level Neonatal 5 Drug Panel, Meconium